VHL is a tumor suppressor gene localized on chromosome 3p25-26. Mutations of the VHL gene were described at first in the heritable von Hippel-Lindau disease and in the sporadic Renal Cell Carcinoma (RCC). More recently, VHL has also been shown to harbor mutations in mesothelioma and small cell lung carcinoma. To date more than 500 mutations have been identified. These mutations are mainly private with only one hot spot at codon 167 associated with pheochromocytoma. The germline mutations are essentially missense while somatic mutations include deletions, insertions and nonsense. To standardize the collection of these informations, facilitate the mutational analysis of the VHL gene and promote the genotype-phenotype analysis, a software package along with a computerized database have been created. The current database and the analysis software are accessible via the internet and world wide web interface at the URL: http://www.umd.necker.fr
INTRODUCTION
The von Hippel-Lindau disease is a dominantly inherited familial cancer syndrome, with an incidence of 1 in 36 000, predisposing to the development of retinal, cerebellar and spinal haemangioblastomas, pancreatic cysts and carcinoma and RCC (1, 2) . RCC, the most frequent malignancy in the adult kidney, is usually sporadic and its phenotype is extremely heterogeneous. Both sporadic and familial RCC bear relation as clear cells subtype accounts for most tumors. It has been postulated that these tumors have a common carcinogenic pathway and that at least one gene should be altered in both forms. This hypothesis has been confirmed with the cloning of the VHL gene and the identification of germline and somatic mutations of this gene in VHL patients and sporadic RCC. The human VHL gene encodes a 213 amino acid (aa) protein expressed in all tissues (3). To understand its functions, different groups have identified and characterized proteins which interacts with pVHL. Three groups have shown that pVHL stably associates with the two regulatory subunits B and C of the transcription elongation factor, elongin (4-6). Duan et al. showed that pVHL can inhibit transcriptional elongation by elongation factor sIII (4). Pause and colleagues showed that the trimeric pVHL-elongin B-C specifically associates with the Hs-CUL-2, a member of the Cdc53 family of proteins (7). Tsuchiya et al. have shown that a novel protein, VBP1, can form a complex with pVHL in vivo (8) but its role remains unknown. Concurrently, investigations were performed on identified mutations of this gene. Today, 314 mutations have been described in VHL families (3, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , 143 reported in sporadic RCC (17, (19) (20) (21) (22) (23) (24) and 49 in cell lines (3, 17, 22, 25) . If most germline VHL mutations are missense alterations, most of the sporadic mutations result in truncated protein. The collection of a large number of mutations is then necessary to understand this discrepancy, to identify key residues in the biological function of the protein and to establish correlations between the localization of the mutation and specific phenotypes.
To handle the flow of all known VHL mutations and study genotype/phenotype relations, we adapted the 'universal mutation database' software to this gene (26) (27) (28) .
DATABASE AND SOFTWARE
The database of VHL mutations was developed using the 'Universal Mutation Database' tool (26) (27) (28) . It contains all mutations localized in the coding region of the VHL gene. In an attempt to standardize the numbering system used to describe VHL mutations, all mutations which have been previously reported using the numbering scheme of Latif et al. (3) have been renumbered. Amino acid positions are derived from the numbering system used in Kuzmin et al. (29) who identified the VHL gene promotor and defined the initiation codon at position +71 from the original sequence described by Latif et al. (3) . The current version of the database contains 507 entries. When the same mutation was reported in more than one article, only the first report was taken into account. For each mutation, information is provided at several levels: at the gene level (exon and codon number, wild type and mutant codon, mutational event, mutation name), at the protein level (wild type and mutant amino acid), at the clinical level (angioma, hemangioblastoma, pheochromocytoma, RCC), at the molecular level (LOH of the second allele) and at the histological level (Robson stage).
The software package contains routines for the analysis of the VHL database that were developed with the 4 th dimension′′ (4D) package from ACI. The use of the 4D SGDB gives access to optimized multicriteria research and sorting tools to select records from any field. Moreover, all routines already developed for other databases were added to the VHL package: (i) 'Position' studies the distribution of mutations at the nucleotide level to identify preferential mutation sites; (ii) 'Mutational events' is comparable to (i) but also indicates the type of mutational event. The result can either be displayed as a table or in a graphic representation; (iii) 'Frequency of mutations' allows one to study the relative distribution of mutations at all sites and to sort them according to their frequency. A graphic representation is also available and displays a cumulative chart of mutation distributions; (iv) 'Frequency of events' is similar to (iii) but also indicates if mutations are localized in a CpG dinucleotide; (v) 'Distribution of mutations' and 'Binary comparison' are two graphical routines which allow one to compare the distribution of mutations in up to eight groups of records and display the result either in one or two graphics; (vi) 'Stat exons' studies the distribution of mutations in the different exons. It enables detection of a statistically significant difference between observed and expected mutations; (vii) 'Insertions and deletions analysis' searches for repeated sequences surrounding the mutation and possibly involved in the mutational mechanism.
Subsequently, the software will be expanded as the database grows and according to the requirements of its users. New functions could be implemented. Table 1 describes a section of the database.
AVAILABILITY
The current database and subsequent updated versions are (will be) available on request to C.B. on floppy disc either Apple or PC formatted. Notification of omissions and errors in the current version as well as specific phenotypic data would be gratefully received by the corresponding author. If you use this database, please cite the present article as reference. The software package is available on a collaborative basis.
The current database and the analysis software will be accessible via the internet and world wide web interface in January 1998 at the URL: http://www.umd.necker.fr
